VRAX
Virax Biolabs Group Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$1.20
+13.21%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 0.21x
- Price / sales
- 115.03x
- Price / cash flow
- -0.21x
Enterprise value
- Enterprise value
- -$4.7M
- EV / sales
- -337.27x
- EV / EBITDA
- 0.59x
- EV / EBIT
- 0.53x
- Market cap
- $1.6M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Mar 1, 2026